{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:06:35Z","timestamp":1794135995221,"version":"4.8.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p>Symptomatic cerebrospinal fluid (CSF) viral escape (sCVE) is reported in people with HIV, who are on ritonavir-boosted protease inhibitor (PI\/r) containing antiretroviral therapy (ART). Management of sCVE includes performing genotypic HIV-1 resistance testing (GRT) on CSF and plasma HIV and changing ART accordingly. Neither GRT nor newer drugs (Dolutegravir and Darunavir\/ritonavir) are routinely available in India. As a result, management of sCVE includes 2 modalities: a) ART intensification by adding drugs that reach therapeutic concentrations in CSF, like Zidovudine, to existing ART or b) Changing to a regimen containing newer boosted PI\/r and integrase strand transfer inhibitor (INSTI) as per GRT or expert opinion. In this retrospective study, we report the outcomes of above 2 modalities in treatment of sCVE in Pune, India.<\/jats:p><jats:p>Fifty-seven episodes of sCVE in 54 people with HIV taking PI\/r-containing ART were identified. Clinical, demographic, laboratory and ART data were recorded. Forty-seven cases had follow-up data available after ART change including measurement of plasma and CSF viral load (VL).<\/jats:p><jats:p>Of the 47 cases, 23 received zidovudine intensification (Group A, median VL: plasma- 290, CSF- 5200\u200acopies\/mL) and 24 received PI\/INSTI intensification (Group B, median VL: plasma- 265, CSF-4750\u200acopies\/mL). CSF GRT was performed in 16 participants: 8 had triple class resistance. After ART change, complete resolution of neurologic symptoms occurred in most participants (Group A: 18, Group B: 17). In Group A, follow-up plasma and CSF VL were available for 21 participants, most of whom achieved virologic suppression (VL &lt; 20\u200acopies\/mL) in plasma (17) and CSF (15). Four participants were shifted to the PI\/INSTI intensification group due to virologic failure (plasma or CSF VL &gt; 200\u200acopies\/mL). In Group B, follow-up plasma and CSF VL were available for 23 participants, most of whom also achieved virologic suppression in plasma (21) and CSF (18). Four deaths were noted, 2 of which were in individuals who interrupted ART.<\/jats:p><jats:p>This is a unique sCVE cohort that was managed with 1 of 2 approaches based on treatment history and the availability of GRT. At least 75% of participants responded to either approach with virologic suppression and improvement in symptoms.<\/jats:p><\/jats:sec>","DOI":"10.1097\/md.0000000000020516","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T05:15:24Z","timestamp":1591852524000},"page":"e20516","source":"Crossref","is-referenced-by-count":12,"title":["Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-7530","authenticated-orcid":false,"given":"Ameet N.","family":"Dravid","sequence":"first","affiliation":[{"name":"Department of Medicine, Ruby Hall Clinic"},{"name":"Department of Medicine, Poona hospital and research centre"},{"name":"Department of Medicine, Noble hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raviraj","family":"Gawali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Poona hospital and research centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun P.","family":"Betha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Poona hospital and research centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avadesh K.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medicine, Poona hospital and research centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahenderkumar","family":"Medisetty","sequence":"additional","affiliation":[{"name":"Department of Medicine, Poona hospital and research centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Natrajan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Poona hospital and research centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind M.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ruby Hall Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmay K.","family":"Saraf","sequence":"additional","affiliation":[{"name":"VMK Diagnostics private limited, Pune"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma S.","family":"Mahajan","sequence":"additional","affiliation":[{"name":"VMK Diagnostics private limited, Pune"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin D.","family":"Kore","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ashwini Sahakari Rugnalaya, Solapur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan M.","family":"Rathod","sequence":"additional","affiliation":[{"name":"Department of Medicine, Apex hospital, Kolhapur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umakant S.","family":"Mahajan","sequence":"additional","affiliation":[{"name":"GeneOmbio Technologies Private limited, Pune, Maharashtra, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Letendre","sequence":"additional","affiliation":[{"name":"University of California, San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rustom S.","family":"Wadia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ruby Hall Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/650538","article-title":"Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy","volume":"50","author":"Canestri","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/QAD.0b013e328355e6b2","article-title":"Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load","volume":"26","author":"Peluso","year":"2012","journal-title":"AIDS"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jinf.2012.04.007","article-title":"Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting","volume":"65","author":"Rawson","year":"2012","journal-title":"J Infect"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s13365-016-0448-1","article-title":"Discordant CSF\/plasma HIV-1 RNA in patients with unexplained low-level viremia","volume":"22","author":"Nightingale","year":"2016","journal-title":"J Neurovirol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/QAI.0000000000001362","article-title":"Temporal patterns and drug resistance in CSF viral escape among ART-experienced HIV-1 infected adults","volume":"75","author":"Mukerji","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/QAD.0000000000002074","article-title":"Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects","volume":"33","author":"P\u00e9rez-Valero","year":"2019","journal-title":"AIDS"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1086\/378300","article-title":"Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication","volume":"37","author":"Wendell","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/QAD.0b013e32832d077c","article-title":"Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment","volume":"23","author":"Garvey","year":"2009","journal-title":"AIDS"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1258\/ijsa.2011.010507","article-title":"HIV encephalitis despite suppressed viremia: a case of compartmentalized viral escape","volume":"22","author":"Bingham","year":"2011","journal-title":"Int J STD AIDS"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jinf.2011.05.011","article-title":"Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus","volume":"63","author":"Bogoch","year":"2011","journal-title":"J Infect"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s13365-013-0175-9","article-title":"CSF viral escape in a patient with HIV-associated neurocognitive disorder","volume":"19","author":"Khoury","year":"2013","journal-title":"J Neurovirol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/aid.2011.0020","article-title":"HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy","volume":"28","author":"Tamarit Mdel","year":"2012","journal-title":"AIDS Res Hum Retrovir"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1089\/aid.2014.0014","article-title":"Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir\/ritonavir monotherapy with plasma HIV-1 RNA suppression","volume":"30","author":"Imaz","year":"2014","journal-title":"AIDS Res Hum Retrovir"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3851\/IMP2530","article-title":"Ongoing HIV replication in cerebrospinal fluid under successful monotherapy","volume":"18","author":"Bierhoff","year":"2013","journal-title":"Antivir Ther"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/cid\/ciu679","article-title":"A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk?","volume":"59","author":"Mangioni","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"omy132","DOI":"10.1093\/omcr\/omy132","article-title":"Symptomatic cerebrospinal fluid HIV- 1 escape in two patients on second - line antiretroviral therapy in Uganda","volume":"2019","author":"Ssebambulidde","year":"2019","journal-title":"Oxf Med Case Reports"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s13365-018-0642-4","article-title":"Incidence of symptomatic CSF viral escape in HIV infected patients receiving atazanavir\/ritonavir (ATV\/r)-containing ART: a tertiary care cohort in western India","volume":"4","author":"Patel","year":"2018","journal-title":"J Neurovirol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/0956462417749421","article-title":"Neurosymptomatic cerebrospinal fluid escape in HIV-2: a case report","volume":"29","author":"Kulkarni","year":"2018","journal-title":"Int J STD AIDS"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"e9969","DOI":"10.1097\/MD.0000000000009969","article-title":"Discordant CSF\/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India","volume":"97","author":"Dravid","year":"2018","journal-title":"Medicine"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2019.03.033","article-title":"Symptomatic HIV CNS viral escape among patients on effective cART","volume":"84","author":"Manesh","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/QAD.0b013e32834a40cd","article-title":"CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy","volume":"25","author":"Ellis","year":"2011","journal-title":"AIDS"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ana.22053","article-title":"Human immunodeficiency virus-associated neurocognitive disorders: mind the gap","volume":"67","author":"McArthur","year":"2010","journal-title":"Ann Neurol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11904-015-0267-7","article-title":"Fluid HIV escape from antiretroviral therapy","volume":"12","author":"Ferretti","year":"2015","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R24-20230915","first-page":"137","article-title":"Central nervous system complications in HIV Disease: HIV-associated neurocognitive disorder","volume":"19","author":"Letendre","year":"2011","journal-title":"Top Antivir Med"},{"key":"R25-20230915","first-page":"1139","article-title":"Controversies in HIV-associated neurocognitive disorders Lancet Neurology NIH Public Access","volume":"13","author":"Nightingale","year":"2014","journal-title":"XXX"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"e0157160","DOI":"10.1371\/journal.pone.0157160","article-title":"Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment","volume":"11","author":"Ed\u00e9n","year":"2016","journal-title":"PLoS One"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/cid\/ciy267","article-title":"Impact of antiretroviral regimens on CSF viral escape in a prospective multicohort study of ART experienced HIV-1 infected adults in the United States","volume":"67","author":"Mukerji","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-013-0159-3","article-title":"Darunavir: a review of its use in the management of HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40265-014-0256-y","article-title":"Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2007.31","article-title":"Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system","volume":"65","author":"Letendre","year":"2008","journal-title":"Arch Neurol"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/QAD.0b013e328317a702","article-title":"Low atazanavir concentrations in cerebrospinal fluid","volume":"23","author":"Best","year":"2009","journal-title":"AIDS"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/cid\/ciu773","article-title":"Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV infected patients are associated with compartmental viral control","volume":"60","author":"Calcagno","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S2055-6640(20)30879-7","article-title":"Highlights of the Global HIV-1 CSF escape consortium meeting, 9 June 2016, Bethesda, MD, USA","volume":"2","author":"Joseph","year":"2016","journal-title":"J virus Erad"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S2055-6640(20)30878-5","article-title":"HIV persistence in the CNS: the final frontier for a cure?","volume":"2","author":"Lewin","year":"2016","journal-title":"J Virus Erad"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial","volume":"18","author":"Hakim","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0b013e32833db9a1","article-title":"Randomized controlled study demonstrating failure of LPV\/r monotherapy in HIV: the role of compartment and CD4-nadir","volume":"24","author":"Gutmann","year":"2010","journal-title":"AIDS"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP3146","article-title":"Evaluation of cerebrospinal fluid virological escape in patients on long-term protease inhibitor monotherapy","volume":"22","author":"Arenas-Pinto","year":"2017","journal-title":"Antivir Ther"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000002442","article-title":"Presence of EBV DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation","volume":"34","author":"Lupia","year":"2019","journal-title":"AIDS"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1128\/AAC.32.2.265","article-title":"Anti-human immunodeficiency virus agent 3\u2032-azido-3\u2032-deoxythymidine inhibits replication of Epstein-Barr virus","volume":"32","author":"Lin","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"R46-20230915","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/cis975","article-title":"Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program","volume":"56","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"R49-20230915","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"Antinori","year":"2007","journal-title":"Neurology"},{"key":"R50-20230915","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1025444225120","article-title":"Screening clinical depression in HIV-seropositive patients using the Hospital Anxiety and Depression Scale","volume":"3","author":"Savard","year":"1999","journal-title":"AIDS Behav"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T11:44:59Z","timestamp":1723031099000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":43,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020516","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]}}}